Legend Biotech (LEGN) Non-Current Debt (2021 - 2025)

Legend Biotech (LEGN) has reported Non-Current Debt for 5 consecutive years, with $319.1 million the latest figure, recorded in Q4 2025.

• Quarterly Non-Current Debt rose 5.94% year-over-year to $319.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $319.1 million (up 5.94% YoY) and the FY2025 annual result came in at $319.1 million, up 5.94% from the prior year.
• Non-Current Debt advanced to $319.1 million in Q4 2025 per LEGN's latest filing, from $171.9 million in the prior quarter.
• Over the last five years, Non-Current Debt for LEGN reached as high as $319.1 million in Q4 2025 and fell as low as $17310.0 in Q2 2021.
• A 5-year average of $232.7 million and a median of $275.9 million in 2023 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2022 — Non-Current Debt soared 116.61% — and 2025, when it plunged 42.04%.
• Year by year, Non-Current Debt stood at $120.5 million in 2021, then surged by 116.61% to $260.9 million in 2022, then climbed by 7.82% to $281.3 million in 2023, then rose by 7.06% to $301.2 million in 2024, then rose by 5.94% to $319.1 million in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $319.1 million, $171.9 million, and $310.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.